Glucose-Dependent Insulinotropic Polypeptide-A Postprandial Hormone with Unharnessed Metabolic Potential

Glucose-dependent insulinotropic polypeptide (GIP) is released from the upper small intestine in response to food intake and contributes to the postprandial control of nutrient disposition, including of sugars and fats. Long neglected as a potential therapeutic target, the GIPR axis has received inc...

Full description

Saved in:
Bibliographic Details
Published in:Annual review of nutrition 2022-08, Vol.42 (1), p.21-44
Main Authors: Guccio, Nunzio, Gribble, Fiona M, Reimann, Frank
Format: Article
Language:English
Subjects:
bone mineral density
diabetes
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - metabolism
food intake
Gastric Inhibitory Polypeptide - metabolism
Gastric Inhibitory Polypeptide - therapeutic use
GIP
Glucose - metabolism
glucose-dependent insulinotropic polypeptide
Humans
incretin
obesity
Obesity - drug therapy
Postprandial Period
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glucose-dependent insulinotropic polypeptide (GIP) is released from the upper small intestine in response to food intake and contributes to the postprandial control of nutrient disposition, including of sugars and fats. Long neglected as a potential therapeutic target, the GIPR axis has received increasing interest recently, with the emerging data demonstrating the metabolically favorable outcomes of adding GIPR agonism to GLP-1 receptor agonists in people with type 2 diabetes and obesity. This review examines the physiology of the GIP axis, from the mechanisms underlying GIP secretion from the intestine to its action on target tissues and therapeutic development.
ISSN:0199-9885
1545-4312
DOI:10.1146/annurev-nutr-062320-113625